SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Considerations in Management for Trans and Gender Diverse Patients with Inherited Cancer Risk

Coad, B; Giblin, J; Walsh, RJ; Kuczkowska, O; von Vaupel-Klein, AM; Berner, A (2021) Considerations in Management for Trans and Gender Diverse Patients with Inherited Cancer Risk. CURRENT GENETIC MEDICINE REPORTS, 9 (4). pp. 59-69. ISSN 2167-4876 https://doi.org/10.1007/s40142-021-00201-6
SGUL Authors: Coad, Elizabeth Susan

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Purpose of Review To best support all patients with inherited cancer risk, we must broaden our scope of practice to consider the needs of the transgender and gender diverse (trans) community. We considered best practice for supporting trans patients including tailored risk assessments and management recommendations. Recent Findings There is limited literature considering trans patient care in cancer genetics. Small case studies have highlighted how medical transition and cancer risk–reducing options intersect with the need for individualised care. Studies have also shown that cancer genetics professionals do not feel prepared to support trans patients. Summary Patient-centred care for trans patients relies on a multidisciplinary team (MDT) engaged in shared decision-making. National guidelines are needed to standardise access to appropriate discussions around risk-reducing options and screening. International collaborative research is required to provide empiric data on the impact of gender-affirming treatments on cancer risk, and more experiential data is needed from trans patients accessing cancer genetics services. Finally, education and training in this area should be formally embedded for all cancer genetics professionals.

Item Type: Article
Additional Information: © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Keywords: Cancer risk, Transgender, Genetics, Personalised care
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Journal or Publication Title: CURRENT GENETIC MEDICINE REPORTS
ISSN: 2167-4876
Dates:
DateEvent
December 2021Published
27 September 2021Published Online
11 August 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Web of Science ID: WOS:000700986900001
URI: https://openaccess.sgul.ac.uk/id/eprint/113762
Publisher's version: https://doi.org/10.1007/s40142-021-00201-6

Actions (login required)

Edit Item Edit Item